Abstract

The present invention relates to a nucleic acid molecule encoding an RNA-guided DNA endonuclease, which is (a) a nucleic acid molecule encoding the RNA-guided DNA endonuclease comprising or consisting of the amino acid sequence of SEQ ID NO: 1 or 3; (b) a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO: 2 or 4; (c) a nucleic acid molecule encoding a RNA-guided DNA endonuclease the amino acid sequence of which is at least 70 % identical to the amino acid sequence of (a); preferably at least 80 % identical, more preferably at least 90 % identical, and most preferred at least 95% identical; (d) a nucleic acid molecule comprising or consisting of a nucleotide sequence which is at least 70 % identical to the nucleotide sequence of (b), preferably at least 80 % identical, more preferably at least 90 % identical, and most preferred at least 95% identical; (e) a nucleic acid molecule which is degenerate with respect to the nucleic acid molecule of (d); or (f) a nucleic acid molecule corresponding to the nucleic acid molecule of any one of (a) to (d) wherein T is replaced by U.

IPC Classes  ?

• C12N 9/22 - Ribonucleases
• C12N 15/55 - Hydrolases (3)
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

The present invention relates to a process for the preparation of a fermentable sugar composition, wherein a polysaccharide composition is treated by at least one glucoamylase enzyme and at least one oligo-1,6-glucosidase enzyme, and wherein the fermentable sugars are removed during the process. Thereby, the otherwise non-fermentable sugars can be utilized in the fermentation process to yield a fermentation product such as an alcohol or an organic acid or amino acid.

IPC Classes  ?

• C12P 7/06 - Ethanol, i.e. non-beverage
• C12P 19/12 - Disaccharides
• C12P 19/16 - Preparation of compounds containing saccharide radicals produced by the action of an alpha-1, 6-glucosidase, e.g. amylose, debranched amylopectin
• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)

Abstract

The present invention relates to a method of producing a 10-hydroxy fatty acid, wherein the method comprises contacting a sample comprising a (9Z) or (9E)-fatty acid with a polypeptide having the activity of an oleate hydratase (EC 4.2,1.53) encoded by a nucleic acid molecule, wherein the nucleic acid molecule is (a) a nucleic acid molecule encoding a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1 or 7; (b) a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO: 2 or 8; (c) a nucleic acid molecule comprising or consisting of a nucleic acid molecule encoding a polypeptide having the activity of an oleate hydratase the amino acid sequence of which is at least 91% identical to the amino acid sequence of SEQ ID NO: 1 or 7; (d) a nucleic acid molecule encoding a polypeptide having the activity of an oleate hydratase and comprising or consisting of a nucleotide sequence which is at least 91 % identical to the nucleotide sequence of SEQ ID NO: 2 or 8; (e) a fragment of the nucleic acid molecule of any of (a) to (d) comprising at least 1341 nucleotides and encoding a polypeptide having the activity of an oleate hydratase; or (f) the nucleic acid sequence of any of (a) to (d) wherein T is U.

IPC Classes  ?

• C12N 9/88 - Lyases (4.)
• C12P 7/64 - FatsFatty oilsEster-type waxesHigher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl groupOxidised oils or fats

Abstract

( LRRC8A ), LRRC8B, LRRC8C, LRRC8D LRRC8E( LRRC8A ), LRRC8B, LRRC8C, LRRC8DLRRC8E( LRRC8A ), LRRC8B, LRRC8C, LRRC8DLRRC8ELRRC8A, LRRC8B, LRRC8C,LRRC8A, LRRC8B, LRRC8C, LRRC8D or LRRC8E gene or the innexin gene is knocked- out, and (ii) enriching cells, wherein the gene of interest is genome edited.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/64 - General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host

Abstract

The present invention relates to the leucine-rich repeat-containing protein 8A (LRRC8A), and/or an activator of LRRC8A, for use in the treatment and/or prevention of a skin condition associated with an altered differentiation of keratinocytes. Preferably, the skin condition associated with an altered differentiation of keratinocytes is psoriasis or dermatitis, preferably atopic dermatitis. The present invention further relates to a method of identifying a compound capable of altering the differentiation of keratinocytes, the method comprising the steps of (a) contacting keratinocytes with a test compound and determining the amount of LRRC8A protein or LRRC8A transcript in said keratinocytes; and (b) comparing the amount of LRRC8A protein or LRRC8A transcript determined in step (a) with the amount of LRRC8A protein or LRRC8A transcript in a control not contacted with said test compound, wherein a change in the amount of LRRC8A protein or LRRC8A transcript after contacting the keratinocytes with the test compound indicates that the test compound is capable of altering the differentiation of keratinocytes. Furthermore, the present invention relates to a method of identifying a compound capable of altering the differentiation of keratinocytes, the method comprising the steps of (a) contacting keratinocytes with a test compound and determining the activity of (a) VRAC(s) comprising LRRC8A in said keratinocytes; and (b) comparing the activity determined in step (a) with the activity in a control not contacted with said test compound, wherein a change in the activity of (a) VRAC(s) comprising LRRC8A after contacting the keratinocytes with the test compound indicates that the test compound is capable of altering the differentiation of keratinocytes. The present invention further relates to an inhibitor of the leucine-rich repeat-containing protein 8A (LRRC8A) for use in the treatment and/or prevention of a skin condition selected from skin injury and impaired wound healing, as well as to a cosmetic method for alleviating the effects of a skin condition on the appearance of the skin of an affected individual, the method comprising topically administering an effective amount of (i) leucine-rich repeat-containing protein 8A (LRRC8A); (ii) an activator of LRRC8A; (iii) LRRC8A and an activator of LRRC8A; or (iv) an inhibitor of LRRC8A.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
• A61P 17/06 - Antipsoriatics
• A61Q 19/00 - Preparations for care of the skin

Abstract

We have identified by molecular cloning a protease which originates from the larvae of Lucilia sericata and which was termed debrilase due to its activities useful for debridement of wounds. Described is a nucleic acid molecule encoding a serine protease having the ability to cleave fibrin and casein which is (a) a nucleic acid molecule encoding the serine protease comprising or consisting of the amino acid sequence of SEQ ID NO: 4 as well as to nucleic acid molecules encoding precursors or fragments of said serine protease; (b) a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO: 3; (c) a nucleic acid molecule encoding a serine protease the amino acid sequence of which is at least 80% identical to the amino acid sequence of (a), preferably at least 85% identical, more preferably at least 90% identical, and most preferred 95% identical; (d) a nucleic acid molecule comprising or consisting of a nucleotide sequence which is at least 80% identical to the nucleotide sequence of (b), preferably at least 85% identical, more preferably at least 90% identical, and most preferred 95% identical; (e) a nucleic acid molecule which is degenerate with respect to the nucleic acid molecule of (b) or (d); or (f) a nucleic acid molecule corresponding to the nucleic acid molecule of any one of (a) to (d) wherein T is replaced by U.

IPC Classes  ?

• C12N 9/48 - Hydrolases (3.) acting on peptide bonds, e.g. thromboplastin, leucine aminopeptidase (3.4)
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61K 38/43 - EnzymesProenzymesDerivatives thereof
• C12P 21/00 - Preparation of peptides or proteins
• C12N 15/57 - Hydrolases (3) acting on peptide bonds (3.4)
• C12N 9/50 - Proteinases
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin

Abstract

The present invention relates to a method for the recombinant production of a serine protease comprising (a) culturing a host cell comprising one or more vectors, wherein the one or more vectors encode in expressible form the serine protease and a proteinaceous inhibitor of the serine protease, wherein the proteinaceous inhibitor of the serine protease is heterologous with respect to the serine protease, under conditions wherein the serine protease and the proteinaceous inhibitor of the serine protease are expressed; or (a') culturing a host cell the genome of which encodes in expressible form the serine protease and a proteinaceous inhibitor of the serine protease, wherein the proteinaceous inhibitor of the serine protease is heterologous with respect to the serine protease, and wherein the coding sequences of the serine protease and/or the proteinaceous inhibitor have been introduced into the host cell genome by applying a CRISPR technology, under conditions wherein the serine protease and the proteinaceous inhibitor of the serine protease are expressed; and (b) isolating the serine protease expressed in step (a) or (a') from the host cell. The present invention also relates to a host cell comprising one or more vectors, wherein the one or more vectors encode in expressible form a serine protease and a proteinaceous inhibitor of the serine protease.

IPC Classes  ?

• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
• C07K 14/81 - Protease inhibitors
• C12N 15/81 - Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
• C12N 15/67 - General methods for enhancing the expression
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material

Abstract

The invention provides a process of isolating or enriching a heavy metal present in a liquid medium. The process comprising the following steps: (a) incubating a suspension containing (i) particulate scrap metal, household waste and/or industrial waste containing a heavy metal in elemental form and (ii) biomass comprising a bacterium, or a combination of two or more bacteria, capable of binding the heavy metal; (b) separating the biomass having bound heavy metal from the suspension of step (a); and (c) isolating the heavy metal from the biomass separated in step (b).

IPC Classes  ?

• C22B 3/24 - Treatment or purification of solutions, e.g. obtained by leaching by physical processes, e.g. by filtration, by magnetic means by adsorption on solid substances, e.g. by extraction with solid resins
• C12N 1/20 - BacteriaCulture media therefor
• C12N 1/22 - Processes using, or culture media containing, cellulose or hydrolysates thereof
• C12N 1/34 - Processes using foam culture
• C22B 3/18 - Extraction of metal compounds from ores or concentrates by wet processes with the aid of microorganisms or enzymes, e.g. bacteria or algae
• C22B 3/00 - Extraction of metal compounds from ores or concentrates by wet processes

Abstract

The present invention relates to compositions of perillic acid compounds and activity enhancing substances, therapeutic and non-therapeutic uses of the compositions as well as a method of preparing the compositions.

IPC Classes  ?

• A61K 8/34 - Alcohols
• A61K 8/36 - Carboxylic acidsSalts or anhydrides thereof
• A61K 8/368 - Carboxylic acidsSalts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
• A61Q 19/00 - Preparations for care of the skin
• A61K 31/19 - Carboxylic acids, e.g. valproic acid

Abstract

The present invention relates to compositions of perillic acid compounds, therapeutic and non-therapeutic uses of the compounds and compositions as well as a method of preparing the composition.

IPC Classes  ?

• A61K 8/36 - Carboxylic acidsSalts or anhydrides thereof
• A61Q 19/00 - Preparations for care of the skin
• A61K 8/06 - Emulsions
• A61K 31/015 - Hydrocarbons carbocyclic

Abstract

The invention relates to a preparation containing (a) at least one NSAID active ingredient and (b) dehydroabietic acid or an extract containing dehydroabietic acid, as a drug.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The invention provides an assay for identifying a bacterium capable of binding elemental heavy metal, comprising the following steps: cultivating a test bacterium in a suitable first culture medium; immersing at least a surface portion of a test tool into the first culture medium for a second predetermined period of time, said surface portion being coated by elemental heavy metal, respectively; removing said test tool from said first culture medium and optionally rinsing the test tool; contacting a second culture medium with the surface portion coated by elemental heavy metal of said test tool removed in the previous step; and identifying the test bacterium as being capable of binding elemental heavy metal from growth of the test bacterium in said second culture medium.

IPC Classes  ?

• C22B 3/24 - Treatment or purification of solutions, e.g. obtained by leaching by physical processes, e.g. by filtration, by magnetic means by adsorption on solid substances, e.g. by extraction with solid resins
• C12R 1/00 - Microorganisms

Abstract

The invention provides an assay for identifying a bacterium capable of binding elemental heavy metal, comprising the following steps: cultivating a test bacterium in a suitable first culture medium; immersing at least a surface portion of a test too! into the first culture medium for a second predetermined period of time, said surface portion being coated by elemental heavy metal, respectively; removing said test tool from said first culture medium and optionally rinsing the test tool; contacting a second culture medium with the surface portion coated by elemental heavy metal of said test tool removed in the previous step; and identifying the test bacterium as being capable of binding elemental heavy metal from growth of the test bacterium in said second culture medium.

IPC Classes  ?

• C22B 3/24 - Treatment or purification of solutions, e.g. obtained by leaching by physical processes, e.g. by filtration, by magnetic means by adsorption on solid substances, e.g. by extraction with solid resins
• C12R 1/00 - Microorganisms

Abstract

Accordingly, the present invention relates to a nucleic acid molecule encoding a protein capable of forming a calcium-activated chloride channel, wherein said nucleic acid molecule comprises or consists of (a) a nucleic acid molecule encoding a protein having the amino acid sequence of SEQ ID NO:1; (b) a nucleic acid molecule having the DNA sequence of SEQ ID NO:2; (c) a nucleic acid molecule having the sequence of SEQ ID NO:2, wherein each thymine is replaced by uracil; (d) a nucleic acid molecule that hybridizes under stringent conditions to the complementary strand of a nucleic acid molecule of (a), (b) or (c); (e) a nucleic acid molecule encoding a protein having at least 97% sequence identity to the protein of (a); or (f) a nucleic acid molecule that is degenerate with respect to the nucleic acid molecule of (b), (c) or (d). The present invention further relates to a protein capable of forming a calcium-activated chloride channel, the use of the nucleic acid molecule of or the protein of the invention for identifying an inhibitor of sweat formation as well as an in vitro method of identifying an inhibitor of sweat formation.

IPC Classes  ?

• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants

Abstract

The present invention relates to proliferating human taste cells, wherein the cells are the cells deposited under the DSMZ deposit accession number DSM ACC3169 or taste cells derived thereof. The present invention further relates to the proliferating human taste cells of the invention for use in research. Further, the present invention relates to in vitro methods for analyzing the signalling response of taste cells to a molecule involved in taste signalling, in vitro methods of identifying agents capable of eliciting a taste response in taste cells as well as in vitro methods of identifying modulators of taste signalling.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12N 5/0793 - Neurons

Abstract

A process of isolating a REE or a group of REE from a solution or dispersion containing said REE or said group of REEs comprising the following steps: (i) preparing a mixture comprising said solution or dispersion and biomass comprising at least one organism selected from any one of the following organism classes: eubacteria, archaea, algae, and fungi, whereby the at least one organism is capable of adsorbing or accumulating said REE or said group of REEs; (ii) incubating said mixture of step (i) for allowing the adsorption or accumulation of said REE or said group of REEs by said biomass; (iii) separating the biomass having adsorbed or accumulated REE(s) from the mixture of step (ii); and (iv) isolating said REE or said group of REEs from said biomass separated in step (iii).

IPC Classes  ?

• C22B 3/18 - Extraction of metal compounds from ores or concentrates by wet processes with the aid of microorganisms or enzymes, e.g. bacteria or algae
• C22B 59/00 - Obtaining rare earth metals

Abstract

A process of isolating a REE or a group of REE from a solution or dispersion containing said REE or said group of REEs comprising the following steps: (i) preparing a mixture comprising said solution or dispersion and biomass comprising at least one organism selected from any one of the following organism classes: eubacteria, archaea, algae, and fungi, whereby the at least one organism is capable of adsorbing or accumulating said REE or said group of REEs; (ii) incubating said mixture of step (i) for allowing the adsorption or accumulation of said REE or said group of REEs by said biomass; (iii) separating the biomass having adsorbed or accumulated REE(s) from the mixture of step (ii); and (iv) isolating said REE or said group of REEs from said biomass separated in step (iii).

IPC Classes  ?

• C22B 3/18 - Extraction of metal compounds from ores or concentrates by wet processes with the aid of microorganisms or enzymes, e.g. bacteria or algae
• C22B 59/00 - Obtaining rare earth metals

Abstract

Accordingly, the present invention relates to a nucleic acid molecule encoding a protein capable of forming a calcium-activated chloride channel, wherein said nucleic acid molecule comprises or consists of (a) a nucleic acid molecule encoding a protein having the amino acid sequence of SEQ ID NO:1; (b) a nucleic acid molecule having the DNA sequence of SEQ ID NO:2; (c) a nucleic acid molecule having the sequence of SEQ ID NO:2, wherein each thymine is replaced by uracil; (d) a nucleic acid molecule that hybridizes under stringent conditions to the complementary strand of a nucleic acid molecule of (a), (b) or (c); (e) a nucleic acid molecule encoding a protein having at least 97% sequence identity to the protein of (a); or (f) a nucleic acid molecule that is degenerate with respect to the nucleic acid molecule of (b), (c) or (d). The present invention further relates to a protein capable of forming a calcium-activated chloride channel, the use of the nucleic acid molecule of or the protein of the invention for identifying an inhibitor of sweat formation as well as an in vitro method of identifying an inhibitor of sweat formation.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants

Abstract

The present invention relates to proliferating human taste cells, wherein the cells are the cells deposited under the DSMZ deposit accession number DSM ACC3169 or taste cells derived thereof. The present invention further relates to the proliferating human taste cells of the invention for use in research. Further, the present invention relates to in vitro methods for analysing the signalling response of taste cells to a molecule involved in taste signalling, in vitro methods of identifying agents capable of eliciting a taste response in taste cells as well as in vitro methods of identifying modulators of taste signalling.

IPC Classes  ?

• C12N 5/079 - Neural cells
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12N 5/0793 - Neurons

Abstract

The present invention relates to a host cell having an elevated expression or activity of an enzyme as compared with the parent cell from which it has been derived, said enzyme having lactoyl-CoA reductase activity. Furthermore, provided is a method of producing lactaldehyde and/or 1,2-propanediol, said method comprising culturing said host cell and/or utilizing said enzyme to produce said compound.

IPC Classes  ?

• C12P 7/18 - Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic polyhydric
• C12P 7/24 - Preparation of oxygen-containing organic compounds containing a carbonyl group
• C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12N 9/10 - Transferases (2.)
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material

Abstract

The present invention relates to the use of compounds which are capable of attenuating skin irritation when they are applied to the skin. Skin irritation can be caused, inter alia, by ingredients of cosmetic or pharmaceutical compositions and/or environmental irritants. In particular, the present invention relates to compounds having the property of antagonizing the activation of the transient receptor potential (TRP) ankyrin 1 (TRPA1) ion channel and the use of said compounds as soothing agents. Such compounds can be used in many fields, particularly in personal-care products, cosmetics, textile and packaging products, pharmaceutical compositions, medical devices,and foodstuffs. The present invention further relates to products and/or pharmaceutical compositions containing said compounds. The present invention also relates to the use of the compounds described herein for the modulation of the taste of a food product.

IPC Classes  ?

• A61K 31/235 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
• A61K 8/00 - Cosmetics or similar toiletry preparations
• A61Q 19/00 - Preparations for care of the skin
• A61P 17/00 - Drugs for dermatological disorders
• A23L 1/00 - Foods or foodstuffs; Their preparation or treatment (preservation thereof in general A23L 3/00)
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to the use of compounds which are capable of producing a cooling sensation when they are brought into contact with the human body. In particular, the present invention relates to the use of compounds modulating TRPM8, and optionally to the use of compounds selectively exhibiting agonist activity at the TRPM8 channel. Such compounds have applications in many fields, particularly in oral and personal hygiene products and foodstuffs, but also in pharmaceutical composition products, cosmetics, textile products and packaging products. The present invention further relates to products containing such compounds and to the medical use of such compounds.

IPC Classes  ?

• A61K 8/41 - Amines
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61Q 11/00 - Preparations for care of the teeth, of the oral cavity or of dentures, e.g. dentifrices or toothpastesMouth rinses
• A61Q 17/02 - Barrier preparationsPreparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings containing insect repellants
• A61Q 19/00 - Preparations for care of the skin

Abstract

The invention relates to a nucleic acid molecule encoding a polypeptide having the activity of a catalase (EC 1.1 1.1.6), which nucleic acid molecule is (a) a nucleic acid molecule encoding a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1; (b) a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO: 2; (c) a nucleic acid molecule comprising or consisting of a nucleic acid molecule encoding a polypeptide having the activity of a catalase the amino acid sequence of which is at least 99% identical to the amino acid sequence of SEQ ID NO: 1, (d) a nucleic acid molecule encoding a polypeptide having the activity of a catalase and comprising or consisting of a nucleotide sequence which is at least 98% identical to the nucleotide sequence of SEQ ID NO: 2, (e) a fragment of the polypeptide of any of (a) to (d) having the activity of a catalase and comprising at least 675 amino acids; or (f) the nucleic acid sequence of any of (a) to (d) wherein T is U.

IPC Classes  ?

• A61K 8/66 - Enzymes
• A61K 38/44 - Oxidoreductases (1)
• A61L 12/08 - Methods or apparatus for disinfecting or sterilising contact lensesAccessories therefor using chemical substances
• A61Q 19/08 - Anti-ageing preparations
• C11D 3/386 - Preparations containing enzymes
• C12N 9/08 - Oxidoreductases (1.), e.g. luciferase acting on hydrogen peroxide as acceptor (1.11)

Abstract

Lucilia sericata and which was termed debrilase due to its activities useful for debridement of wounds. Described is a nucleic acid molecule encoding a serine protease having the ability to cleave fibrin and casein which is (a) a nucleic acid molecule encoding the serine protease comprising or consisting of the amino acid sequence of SEQ ID NO: 4 as well as to nucleic acid molecules encoding precursors or fragments of said serine protease; (b) a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO: 3; (c) a nucleic acid molecule encoding a serine protease the amino acid sequence of which is at least 80% identical to the amino acid sequence of (a), preferably at least 85% identical, more preferably at least 90% identical, and most preferred 95% identical; (d) a nucleic acid molecule comprising or consisting of a nucleotide sequence which is at least 80% identical to the nucleotide sequence of (b), preferably at least 85% identical, more preferably at least 90% identical, and most preferred 95% identical; (e) a nucleic acid molecule which is degenerate with respect to the nucleic acid molecule of (b) or (d); or (f) a nucleic acid molecule corresponding to the nucleic acid molecule of any one of (a) to (d) wherein T is replaced by U.

IPC Classes  ?

• C12N 9/48 - Hydrolases (3.) acting on peptide bonds, e.g. thromboplastin, leucine aminopeptidase (3.4)
• C12N 9/50 - Proteinases
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 15/57 - Hydrolases (3) acting on peptide bonds (3.4)
• C12P 21/00 - Preparation of peptides or proteins
• A61K 38/43 - EnzymesProenzymesDerivatives thereof
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

The present invention relates to a nucleic acid molecule encoding a polypeptide having cytochrome P450 monooxygenase activity, wherein said polypeptide comprises a reductase domain that deviates by at least one mutation from (a) the reductase domain of cytochrome P450 BM3, wherein the reductase domain of cytochrome P450 BM3 is represented by SEQ ID NO: 1; or (b) a reductase domain having at least 95% sequence identity to SEQ ID NO:1; and wherein said mutation(s) result(s) in an increased cytochrome P450 monooxygenase activity as compared to a polypeptide comprising the reductase domain of SEQ ID NO: 1. The present invention also relates to a vector comprising the nucleic acid molecule of the invention and a host transformed with the vector. Furthermore, the invention relates to a method of producing a polypeptide comprising culturing the host of the invention as well as to a polypeptide encoded by the nucleic acid molecule of the invention or produced by the method of the invention. The present invention further relates to the use of the polypeptide of the invention in biotransformation or fine chemical synthesis, to an oligo- or polynucleotide which specifically hybridizes to the nucleic acid molecule of the invention as well as to a composition and to a kit.

IPC Classes  ?

• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase

Abstract

The present invention relates to a novel nucleic acid molecule encoding (I) a polypeptide having the activity of a glucose oxidase (EC 1.1.3.4); or (II) a fragment of the polypeptide of (I) having the activity of a glucose oxidase and comprising at least 400 amino acids. Moreover, the invention relates to a vector encoding the nucleic acid molecule, a host cell transformed, transduced or transfected with the vector, a the protein encoded by the nucleic acid molecule, and compositions comprising said nucleic acid molecule, vector, host cell, protein or combinations thereof.

IPC Classes  ?

• C12N 9/04 - Oxidoreductases (1.), e.g. luciferase acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)

Abstract

The present invention relates to a nucleic acid molecule encoding a chimeric protein having the biochemical activity of a surface active protein, wherein said chimeric protein comprises: (a) an N-terminal portion of a first surface active protein, wherein the N-terminal portion is devoid of between 0 and 10 of the most N-terminal amino acids of the mature first surface active protein; and, C-terminally thereof, (b) a C-terminal portion of a second surface active protein, wherein the C-terminal portion is devoid of between 0 and 10 of the most C-terminal amino acids of the mature second surface active protein. The present invention further relates to a vector, a non-human host and a method for the production of a chimeric protein having the biochemical activity of a surface active protein. In addition, the present invention relates to a chimeric protein encoded by the nucleic acid molecule of the invention and a composition comprising the chimeric protein. The chimeric protein may only consist of the above mentioned core of (a) and (b), but may also be flanked by additional components of the core, i.e. (a) or (b) or by (an) additional complete core(s) (a) and (b). The present invention furthermore relates to a method of coating and/or impregnating a material, comprising contacting the material with the chimeric protein or the composition of the invention.

IPC Classes  ?

• C07K 14/37 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from fungi
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• C09D 189/00 - Coating compositions based on proteinsCoating compositions based on derivatives thereof

Abstract

The present invention relates to a method of producing a peptide consisting of the amino acids 63 to 110 of dermcidin (SEQ ID NO: 3) comprising (a) culturing a host cell carrying a nucleic acid molecule encoding the peptide in an expressible form, and (b) optionally isolating the peptide from the culture. Furthermore, the invention relates to a nucleic acid molecule encoding a fusion protein comprising or consisting of (a) a peptide heterologous with regard to dermcidin protein-tag; and, C-terminally thereof (b) a peptide having the antimicrobial activity of dermcidin wherein the fusion protein contains an arginine residue located immediately N-terminally of the peptide of (b).

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12P 21/00 - Preparation of peptides or proteins

Abstract

We have identified by molecular cloning a protease which originates from the larvae of Lucilia sericata and which was termed debrilase due to its activities useful for debridement of wounds. Described is a nucleic acid molecule encoding a serine protease having the ability to cleave fibrin and casein which is (a) a nucleic acid molecule encoding the serine protease comprising or consisting of the amino acid sequence of SEQ ID NO: 4 as well as to nucleic acid molecules encoding precursors or fragments of said serine protease; (b) a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO: 3; (c) a nucleic acid molecule encoding a serine protease the amino acid sequence of which is at least 80 % identical to the amino acid sequence of (a), preferably at least 85 % identical, more preferably at least 90 % identical, and most preferred 95% identical; (d) a nucleic acid molecule comprising or consisting of a nucleotide sequence which is at least 80 % identical to the nucleotide sequence of (b), preferably at least 85 % identical, more preferably at least 90 % identical, and most preferred 95% identical; (e) a nucleic acid molecule which is degenerate with respect to the nucleic acid molecule of (b) or (d); or (f) a nucleic acid molecule corresponding to the nucleic acid molecule of any one of (a) to (d) wherein T is replaced by U.

IPC Classes  ?

• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61K 38/43 - EnzymesProenzymesDerivatives thereof
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

Abstract

We have identified by molecular cloning a protease which originates from the larvae of Lucilia sericata and which was termed debrilase due to its activities useful for debridement of wounds. Described is a nucleic acid molecule encoding a serineprotease having the ability to cleave fibrin and casein which is (a) a nucleic acid molecule encoding the serine protease comprisingor consisting of the amino acid sequence of SEQ ID NO: 4 as well as to nucleic acid molecules encoding precursors or fragments of said serine protease; (b) a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO: 3; (c) a nucleic acid molecule encoding a serine protease the amino acid sequence of which is at least 80 % identical to the amino acid sequence of (a), preferably at least 85 % identical, more preferably at least 90 % identical, and most preferred 95% identical; (d) a nucleic acid molecule comprising or consisting of a nucleotide sequence which is at least 80 % identical to the nucleotide sequenceof (b), preferably at least 85 % identical, more preferably at least 90 % identical, and most preferred 95% identical; (e) a nucleic acid molecule which is degenerate with respect to the nucleic acid molecule of (b) or (d); or (f) a nucleic acid molecule corresponding to the nucleic acid molecule of any one of (a) to (d) wherein T is replaced by U.

IPC Classes  ?

• A61K 38/43 - EnzymesProenzymesDerivatives thereof
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
• C12N 15/62 - DNA sequences coding for fusion proteins

Abstract

The present invention relates to a cyanide-free process of isolating precious metal gold from a particulate material containing said metal, comprising the following steps of (i) preparing an aqueous mixture containing said particulate material and biomass comprising having an S-LAYER or archaea having an S-LAYER; eubacteria and archaea, algae, and fungi; said biomass being capable of adsorbing said metal; (ii) incubating said aqueous mixture of step (i) for allowing binding of said metal to said biomass; (iii) separating the biomass having bound metal from the aqueous mixture of step (ii); and (iv) isolating the metal from said biomass separated in step (iii).

IPC Classes  ?

• C22B 11/00 - Obtaining noble metals
• C22B 3/18 - Extraction of metal compounds from ores or concentrates by wet processes with the aid of microorganisms or enzymes, e.g. bacteria or algae

Abstract

The present invention relates to a cyanide-free process of isolating precious metal gold from a particulate material containing said metal, comprising the following steps of (i)prepar-ing an aqueous mixture containing said particulate material and biomass comprising having an S--LAYER or archaea having an S-LAYER; eubacte-ria and archaea, algae, and fungi; said biomass be-ing capable of adsorbing said metal; (ii) incubating said aqueous mixture of step (i) for allowing bind-ing of said metal to said biomass; (iii) separating the biomass having bound metal from the aqueous mixture of step (ii); and (iv) isolating the metal from said biomass separated in step (iii).

IPC Classes  ?

• C22B 3/18 - Extraction of metal compounds from ores or concentrates by wet processes with the aid of microorganisms or enzymes, e.g. bacteria or algae
• C22B 11/00 - Obtaining noble metals